Published in Clin Pharmacol Ther on January 13, 1971
Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding. Br J Clin Pharmacol (1975) 1.76
Plasma protein binding interaction between phenytoin and valproic acid in vitro. Br J Clin Pharmacol (1978) 1.34
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Analysis of free drug fractions using near-infrared fluorescent labels and an ultrafast immunoextraction/displacement assay. Anal Chem (2006) 1.15
Plasma protein binding of phenytoin in 100 epileptic patients. Br J Clin Pharmacol (1982) 1.14
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol (1978) 1.08
Should we routinely measure free plasma phenytoin concentration? Br J Clin Pharmacol (1984) 1.07
Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy. Br Med J (Clin Res Ed) (1982) 1.06
Effect of sodium valproate on plasma protein binding of diphenylhydantoin. J Neurol Neurosurg Psychiatry (1977) 1.04
Alteration of drug-protein binding in renal disease. Clin Pharmacokinet (1984) 0.99
Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol (1984) 0.96
Serum protein binding of valproic acid and its displacement by palmitic acid in vitro. Br J Clin Pharmacol (1979) 0.94
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Ultrafiltration vs equilibrium dialysis for determination of free fraction. Clin Pharmacokinet (1984) 0.92
The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin. Clin Pharmacokinet (1984) 0.91
The diabetic bladder. Proc R Soc Med (1974) 0.91
Characterization of interaction kinetics between chiral solutes and human serum albumin by using high-performance affinity chromatography and peak profiling. J Chromatogr A (2011) 0.87
Altered drug binding to serum proteins in pregnant women: therapeutic relevance. J R Soc Med (1981) 0.87
Serum protein binding and free concentration of phenytoin and phenobarbitone in pregnancy. Br J Clin Pharmacol (1982) 0.87
Serum protein binding of diazepam and its displacement by valproic acid in vitro. Br J Clin Pharmacol (1981) 0.84
Valproic acid and diazepam interaction in vivo. Br J Clin Pharmacol (1982) 0.81
Plasma protein binding of phenytoin in the aged: in vivo studies. Br J Clin Pharmacol (1982) 0.81
CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. Br J Clin Pharmacol (1976) 0.80
'MacDope': a simulation of drug disposition in the human body: applications in clinical pharmacokinetics. Br J Clin Pharmacol (1980) 0.79
Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. Br Heart J (1975) 0.78
Studies in man of phenytoin absorption and its implications. J Neurol Neurosurg Psychiatry (1975) 0.78
Disposition of anticonvulsants in childhood. Clin Pharmacokinet (1989) 0.77
Entry of five antifungal agents into the ovine lung. Antimicrob Agents Chemother (1987) 0.76
Some potential interactions between prescribed drugs and over-the-counter drug products. Calif Med (1972) 0.75
Effect of febrile illness and its treatment on anticonvulsant levels in children. CMAJ (1986) 0.75
Spuriously high values of unbound drug fraction in serum as determined by the new ultrafree anticonvulsant drug filters. Br J Clin Pharmacol (1981) 0.75
Anticonvulsant pharmacokinetics. Proc R Soc Med (1974) 0.75
Effect of halofenate on the serum binding of phenytoin. Br J Clin Pharmacol (1977) 0.75
Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ (2000) 8.10
Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J (1969) 4.21
Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet (1989) 2.96
Effect of environmental factors on drug metabolism: decreased plasma half-life of antipyrine in workers exposed to chlorinated hydrocarbon insecticides. Clin Pharmacol Ther (1969) 2.75
Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med (1978) 2.68
Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol (1974) 2.64
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand (1976) 2.34
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther (2010) 2.21
Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J (1971) 2.19
Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J (1970) 2.13
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr (1982) 2.07
Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci (1967) 2.05
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther (1985) 1.87
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Enhancement of glucuronide-conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital. N Engl J Med (1966) 1.83
The discharge from vibration-sensitive receptors in the monkey foot. Exp Neurol (1966) 1.82
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg (1999) 1.67
Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances. Proc R Soc Med (1965) 1.67
Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1985) 1.67
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992) 1.66
Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun (1999) 1.66
Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. J Med Genet (1971) 1.66
Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol (1975) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med (2000) 1.57
Disease and acetylation polymorphism. Clin Pharmacokinet (1977) 1.56
Human immunodeficiency virus infection in childhood, adolescence, and pregnancy: a status report and national research agenda. Pediatrics (1989) 1.55
Acetaminophen: potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science (1979) 1.54
Clinical pharmacokinetics in infants and children. Clin Pharmacokinet (1976) 1.49
Lamotrigine and toxic epidermal necrolysis. Lancet (1996) 1.48
Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther (1997) 1.48
High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation. Lancet (1982) 1.46
Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J (2003) 1.44
Morphine metabolism in children. Br J Clin Pharmacol (1989) 1.44
Hypothermic effect of apomorphine in the mouse. J Pharm Pharmacol (1972) 1.43
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Therapeutic drug monitoring of anticonvulsants. State of the art. Clin Pharmacokinet (1990) 1.42
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet (1977) 1.41
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther (1992) 1.41
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther (1981) 1.41
Early onset discordant growth in a successful monochorionic twin pregnancy. BJOG (2002) 1.39
[Triazolam for the last time?]. Tidsskr Nor Laegeforen (1991) 1.39
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther (2010) 1.38
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther (1988) 1.37
The formation of bilirubin and p-nitrophenyl glucuronides by rabbit liver. Biochem J (1966) 1.36
Drug utilization 90%--a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol (1998) 1.35
Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther (1978) 1.33
Effect of phenobarbital on hyperbilirubinemia and glucuronide formation in newborns. Am J Dis Child (1970) 1.33
Proteinases in bone resorption: obvious and less obvious roles. Clin Chim Acta (2000) 1.33
Morphine metabolism in cancer patients on increasing oral doses--no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol (1983) 1.33
New possibilities for adrenergic modulation of ganglionic transmission. Pharmacol Rev (1966) 1.32
Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther (1985) 1.30
Clinical pharmacology and primary health care in Europe--a gap to bridge. The WHO Working Group on Clinical Pharmacology in Europe. Eur J Clin Pharmacol (1990) 1.30
The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden. Eur J Clin Pharmacol (1975) 1.30
Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid. Clin Pharmacol Ther (1972) 1.26
Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther (2001) 1.25
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Clinical pharmacology and the provision of drug information. Eur J Clin Pharmacol (1992) 1.25
Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol (1982) 1.24
Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol (1985) 1.23
Increased plasma binding of quinidine after surgery: a preliminary report. Eur J Clin Pharmacol (1976) 1.23
Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man. Eur J Clin Pharmacol (1976) 1.23
Concentrations of chloroquine and desethylchloroquine in capillary blood dried on filter paper during and after treatment of Tanzanian children infected with Plasmodium falciparum. Trop Med Parasitol (1986) 1.22
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol (1985) 1.22
Determination of chloroquine and its desethyl metabolite in whole blood: an application for samples collected in capillary tubes and dried on filter paper. Ther Drug Monit (1985) 1.21
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther (1995) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol (1983) 1.21
Vasoconstriction in isolated blood-perfused rabbit lungs and its inhibition by cresols. Acta Physiol Scand (1966) 1.20
Comparative efficacy of aspirin and acetaminophen in the reduction of fever in children. Arch Intern Med (1981) 1.20
Pharmaceutic factors affecting pediatric compliance. Pediatrics (1975) 1.19
Surgical treatment of acute malignant large bowel obstruction. Eur J Surg (1992) 1.19
Prednisolone excretion in human milk. J Pediatr (1985) 1.19
Clinical pharmacology of antimicrobials in premature infants. II. Ampicillin, methicillin, oxacillin, neomycin, and colistin. Pediatrics (1967) 1.17
Summary of workshop: early discharge and neonatal hyperbilirubinemia. Pediatrics (1995) 1.15
A clinical look at the problem of drugs in pregnancy and their effect on the fetus. Can Med Assoc J (1975) 1.15
Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther (1976) 1.15
Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci (1980) 1.13
Morphine kinetics in cancer patients. Clin Pharmacol Ther (1981) 1.12
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol (1989) 1.12
The disposition of chloroquine in healthy Nigerians after single intravenous and oral doses. Br J Clin Pharmacol (1987) 1.11
Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol (1989) 1.11
The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol (1990) 1.11
Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis (1977) 1.10
Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther (1978) 1.10
Placental passage of oxazepam and its metabolism in mother and newborn. Clin Pharmacol Ther (1979) 1.09
Comment on Stanford et al.: Traditional native tissue vs mesh-augmented pelvic organ prolapse repairs: providing an accurate interpretation of current literature. Int Urogynecol J (2012) 1.09
Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics (1975) 1.09